Geode Capital Management LLC Purchases 151,480 Shares of Alnylam Pharmaceuticals, Inc. $ALNY

Geode Capital Management LLC grew its position in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 6.1% during the fourth quarter, HoldingsChannel reports. The firm owned 2,650,722 shares of the biopharmaceutical company’s stock after buying an additional 151,480 shares during the period. Geode Capital Management LLC’s holdings in Alnylam Pharmaceuticals were worth $1,056,884,000 at the end of the most recent quarter.

A number of other institutional investors also recently modified their holdings of the company. Optimist Retirement Group LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $383,000. Kestra Investment Management LLC bought a new stake in shares of Alnylam Pharmaceuticals in the 4th quarter valued at $2,391,000. Allstate Corp boosted its stake in shares of Alnylam Pharmaceuticals by 115.0% in the 4th quarter. Allstate Corp now owns 9,829 shares of the biopharmaceutical company’s stock valued at $3,909,000 after purchasing an additional 5,258 shares during the last quarter. Legal & General Group Plc boosted its stake in shares of Alnylam Pharmaceuticals by 8.3% in the 4th quarter. Legal & General Group Plc now owns 961,496 shares of the biopharmaceutical company’s stock valued at $382,339,000 after purchasing an additional 73,716 shares during the last quarter. Finally, Simplify Asset Management Inc. boosted its stake in shares of Alnylam Pharmaceuticals by 43.3% in the 4th quarter. Simplify Asset Management Inc. now owns 1,109 shares of the biopharmaceutical company’s stock valued at $441,000 after purchasing an additional 335 shares during the last quarter. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Stock Down 1.0%

Alnylam Pharmaceuticals stock opened at $301.98 on Friday. The company has a quick ratio of 3.06, a current ratio of 3.13 and a debt-to-equity ratio of 0.94. Alnylam Pharmaceuticals, Inc. has a 12-month low of $284.28 and a 12-month high of $495.55. The firm’s fifty day moving average is $309.38 and its 200 day moving average is $354.73. The company has a market capitalization of $40.32 billion, a PE ratio of 82.51 and a beta of 0.31.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its earnings results on Thursday, April 30th. The biopharmaceutical company reported $1.99 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.87 by $1.12. Alnylam Pharmaceuticals had a net margin of 11.72% and a return on equity of 85.76%. The company had revenue of $1.17 billion for the quarter, compared to the consensus estimate of $1.12 billion. During the same quarter in the previous year, the company earned ($0.44) EPS. Alnylam Pharmaceuticals’s quarterly revenue was up 96.4% compared to the same quarter last year. As a group, sell-side analysts predict that Alnylam Pharmaceuticals, Inc. will post 7.36 EPS for the current fiscal year.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CEO Yvonne Greenstreet sold 6,799 shares of the company’s stock in a transaction on Monday, March 2nd. The shares were sold at an average price of $327.65, for a total transaction of $2,227,692.35. Following the transaction, the chief executive officer owned 98,628 shares in the company, valued at approximately $32,315,464.20. This represents a 6.45% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Melissa Mclaughlin sold 2,286 shares of the company’s stock in a transaction on Monday, April 6th. The stock was sold at an average price of $330.42, for a total transaction of $755,340.12. Following the transaction, the insider owned 9,443 shares in the company, valued at approximately $3,120,156.06. The trade was a 19.49% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 21,255 shares of company stock worth $6,930,337 over the last ninety days. 0.86% of the stock is owned by corporate insiders.

Wall Street Analysts Forecast Growth

ALNY has been the topic of a number of analyst reports. Morgan Stanley reduced their price objective on shares of Alnylam Pharmaceuticals from $495.00 to $408.00 and set an “equal weight” rating on the stock in a research note on Friday, January 30th. Canaccord Genuity Group upped their price objective on shares of Alnylam Pharmaceuticals from $415.00 to $429.00 and gave the company a “buy” rating in a research note on Tuesday, February 17th. Needham & Company LLC reduced their price objective on shares of Alnylam Pharmaceuticals from $529.00 to $510.00 and set a “buy” rating on the stock in a research note on Thursday, February 12th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $330.00 price objective (down from $522.00) on shares of Alnylam Pharmaceuticals in a research note on Monday, March 16th. Finally, Freedom Capital upgraded shares of Alnylam Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, February 17th. Two investment analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and six have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $463.13.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc (NASDAQ: ALNY) is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics. Founded to translate the scientific discovery of RNAi into new medicines, Alnylam applies small interfering RNA (siRNA) technology to silence disease-causing genes. The company develops therapies designed to provide durable disease modification by targeting underlying genetic drivers across a range of rare and more prevalent conditions.

Alnylam has advanced multiple siRNA-based products into commercialization, initially using lipid nanoparticle delivery and more recently employing GalNAc-conjugate chemistry to enable targeted delivery to the liver with subcutaneous dosing.